{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-007703","form_type":"8-K","ticker":"RTGN","cik":"0001836295","company_name":"RetinalGenix Technologies Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.179751+00:00","generated_at":"2026-05-26T09:25:35.013253+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"RetinalGenix amends warrant to bar exercise until 2030 or 3 yrs after uplisting","bullets":["Amendment restricts exercise of 28,014,540-share pre-funded warrant held by Sanovas Ophthalmology, LLC.","New exercise limitation: earlier of Feb 1, 2030 or 3rd anniversary of uplisting to Nasdaq or NYSE American.","CEO Jerry Katzman signed for both company and holder (Sanovas Ophthalmology, LLC).","No other terms of the warrant were modified; $100 consideration paid."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-007703","json":"https://secwatch.observer/filing/0001493152-25-007703.json","markdown":"https://secwatch.observer/filing/0001493152-25-007703.md","text":"https://secwatch.observer/filing/0001493152-25-007703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836295/000149315225007703/0001493152-25-007703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836295/000149315225007703/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T09:25:35.013253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}